
21 Jan Evotec International
Christine Guenther, M.D., Ph.D., Executive Vice President, Head of Global Cell Therapy Translation, Managing Director Evotec Modena
Hamburg, Germany
(NASDAQ : EVT)
Evotec is a biotechnology company focused on delivering highly effective new therapeutics to patients. The company leverages its multimodality platforms for proprietary projects and pipeline co-creation with partners including pharma, biotech, academics, and other healthcare stakeholders. Our business model is flexible, ranging from service-based support to strategic partnerships. Within cell therapy, Evotec offers a fully integrated end-to-end platform to move iPSC-based from inception to the clinic, including in-house GMP manufacturing capabilities with clinical supply. Our proprietary iPSC-based cell therapy pipeline is one of the broadest in the industry and includes anti-tumor therapies (NK cells, macrophages, αβ T cells, γδ T cells), regenerative therapies (beta cells, cardiomyocytes, photoreceptors) and immune-modulation therapies. In addition, Evotec provides integrated drug development solutions, covering safety assessment, CMC, process and analytical development, regulatory and clinical services for autologous and allogeneic cell therapy candidates.